Higher sales in most of its businesses contributed to a 4% increase in comparable sales for Philips Healthcare in its third quarter.
For the period (end-September 30), the Andover, MA-based vendor had comparable sales of 2.1 billion euros ($2.9 billion U.S.), compared with the 1.8 billion euros ($2.5 billion U.S.) reported in the third quarter of 2009.
Philips had third-quarter earnings before interest, taxation, and amortization (EBITA) of 282 million euros ($392.4 million U.S.), up from EBITA of 175 million euros ($243.5 million U.S.) in the same quarter last year.
Higher sales were produced by Philips' home healthcare solutions and patient care and clinical informatics units. On a regional basis, North American comparable sales were broadly in line with the third quarter of 2009, while markets outside of North America were up 7%, Philips said. The company also noted that key emerging markets turned in double-digit growth in comparable sales.
In other positive developments, currency-comparable equipment order intake climbed 7%, including notable improvements in the firm's imaging systems division. North American equipment orders climbed 11%, while order intake outside of North America was 2% higher (including 20% equipment order growth in emerging markets), Philips said.
Related Reading
Philips teams with DHS Systems, October 12, 2010
Philips nets PET/CT award, September 16, 2000
Philips awarded 2 telehealth contracts, August 31, 2010
Philips unveils iE33 enhancements, August 30, 2010
Philips debuts point-of-care ultrasound unit, August 26, 2010
Copyright © 2010 AuntMinnie.com















![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&fit=crop&h=112&q=70&w=112)

